Skip to main content
SpringerLink
Log in

Atypische subtrochantäre Femurfraktur unter Alendronsäuretherapie trotz intramedullärem Implantat

Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant

  • Kasuistiken
  • Published:
Der Unfallchirurg Aims and scope Submit manuscript

Zusammenfassung

Es existiert eine Vielzahl von Fallberichten über Frauen mit einer Langzeit-Bisphosphonattherapie, die infolge eines inadäquaten Traumas eine atypische subtrochantäre oder Femurschaftfraktur erlitten haben.

Der vorliegende Fall berichtet über eine Patientin, welche sich eine subtrochtäre Femurfraktur bei einliegendem AO-Femurverriegelungsnagel zugezogen hatte.

Abstract

There are a number of case reports about women undergoing long-term bisphosphonate therapy who have suffered an atypical subtrochanteric or femoral shaft fracture due to an inadequate trauma.

The present case reports on a patient who underwent a subtrochanteric femur fracture with the inserted AO femur interlocking nail.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and Diaphyseal femur fractures in patients treated with Alendronate: A register-based national cohort study. J Bone Miner Res 24:1095–1102

    Article  CAS  PubMed  Google Scholar 

  2. Alfahad A, Thet EM, Radwan F et al (2012) Spontaneous Incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report. J Med Case Rep 6:272

    Article  PubMed  PubMed Central  Google Scholar 

  3. Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362(19):1761–1771

    Article  CAS  PubMed  Google Scholar 

  4. Cecilia D, Jódar E, Fernández C et al (2009) Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int 20(6):903–910

    Article  CAS  PubMed  Google Scholar 

  5. Dachverband Osteologie e.V. (2014) S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. Kurzfassung und Langfassung

  6. Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Jt Surg Br 89:349–353

    Article  Google Scholar 

  7. Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20(8):1353–1362

    Article  CAS  PubMed  Google Scholar 

  8. Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22(5):346–350

    Article  PubMed  Google Scholar 

  9. Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783–789

    Article  CAS  PubMed  Google Scholar 

  10. Rizzoli R, Akesson K, Bouxsein M et al (2011) Subtrochanteric fractures after longterm treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22(2):373–390

    Article  CAS  PubMed  Google Scholar 

  11. Shane E, Burr D, Ebeling PR et al (2010) American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 11:2267–2294

    Article  Google Scholar 

  12. Sloan AV, Martin JR, Li S, Li J (2010) Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 47(2):235–240

    Article  CAS  PubMed  Google Scholar 

  13. Tonino RP, Meunier PJ, Emkey R et al (2000) Skeletal benefits of alendronate: 7‑year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109–3115

    CAS  PubMed  Google Scholar 

  14. Watts NB (2014) Long-term risks of bisphosphonate therapy. Arq Bras Endocrinol Metab 58(5):523–529

    Article  Google Scholar 

  15. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71:186–190

    Article  CAS  PubMed  Google Scholar 

  16. Wells GA, Cranney A, Peterson J et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. doi:10.1002/14651858.CD001155.pub2

    Google Scholar 

  17. Yang Y‑X, Lewis JD, Epstein S et al (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947–2953

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orthopädische Klinik, Herzogin Elisabeth Hospital, Leipziger Straße 24, 38124, Braunschweig, Deutschland

    H.-P. Sobotta

  2. Klinik für Unfallchirurgie und Orthopädische Chirurgie, Städtisches Klinikum Braunschweig, Braunschweig, Deutschland

    T. Gösling

Authors
  1. H.-P. Sobotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Gösling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.-P. Sobotta.

Ethics declarations

Interessenkonflikt

H.-P. Sobotta und T. Gösling geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

Additional information

Redaktion

W. Mutschler, München

H. Polzer, München

B. Ockert, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sobotta, HP., Gösling, T. Atypische subtrochantäre Femurfraktur unter Alendronsäuretherapie trotz intramedullärem Implantat. Unfallchirurg 120, 171–175 (2017). https://doi.org/10.1007/s00113-016-0270-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00113-016-0270-5

Schlüsselwörter

Keywords

Search

Navigation